No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T20:28:37.988Z. Latest historical point 2026-03-26. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Zentalis Pharmaceuticals, Inc. (ZNTL) stock was $2.67 as of Oct 6, 2026, 4:00 PM EDT, down 3.96% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +72.2% · 3-year avg -48.3%/yr · 5-year avg -47.3%/yr
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer.
Biotechnology · San Diego, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2024-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 10, 2026
35 days away
EPS Estimate
-0.58
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.59
vs Estimate
$-0.49
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ZNTL | $190.07M | $2.67 | -3.96% | +72.22% | -47.34% | N/A | N/A |
| 2ELDN | $189.11M | $2.45 | -2.00% | -11.92% | -15.17% | -37.18% | vs ZNTL |
| 3RXST | $192.49M | $4.65 | -2.31% | -45.75% | -19.19% | N/A | vs ZNTL |
| 4SRZN | $197.18M | $26.37 | -9.47% | +112.02% | -20.80% | N/A | vs ZNTL |
| 5ANTX | $182.60M | $5.07 | -9.63% | +328.54% | N/A | N/A | vs ZNTL |
| 6XGN | $197.87M | $8.19 | -3.19% | -22.71% | -8.40% | N/A | vs ZNTL |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 9 analysts
Average Price Target
$7.33
+174.7% upside
Low
$5.00
Current
$2.67
High
$10.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.60 | $-0.55 | $-0.40 | 6 |
| Quarter ending Dec 2026 | $-0.58 | $-0.51 | $-0.38 | 6 |
| Quarter ending Mar 2027 | $-0.53 | $-0.53 | $-0.53 | 2 |
| Quarter ending Jun 2027 | $-0.52 | $-0.52 | $-0.52 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.36 | $-2.08 | $-1.35 | 8 |
| FY 2027 | $-2.41 | $-1.93 | $-1.44 | 8 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $1.19M | $1.19M | $1.19M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $1.15M | $2.14M | $3.23M | 9 |
| FY 2027 | $9.30M | $9.35M | $9.40M | 7 |
